

Odile Beyne-Rauzy

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/7334625/publications.pdf>

Version: 2024-02-01

94
papers

5,198
citations

117625

34
h-index

85541

71
g-index

97
all docs

97
docs citations

97
times ranked

5269
citing authors

#	ARTICLE	IF	CITATIONS
1	Prognostic Score Including Gene Mutations in Chronic Myelomonocytic Leukemia. <i>Journal of Clinical Oncology</i> , 2013, 31, 2428-2436.	1.6	462
2	A randomized phase 3 study of lenalidomide versus placebo in RBC transfusion-dependent patients with Low-/Intermediate-1-risk myelodysplastic syndromes with del5q. <i>Blood</i> , 2011, 118, 3765-3776.	1.4	424
3	Prognostic factors for response and overall survival in 282 patients with higher-risk myelodysplastic syndromes treated with azacitidine. <i>Blood</i> , 2011, 117, 403-411.	1.4	348
4	Luspatercept in Patients with Lower-Risk Myelodysplastic Syndromes. <i>New England Journal of Medicine</i> , 2020, 382, 140-151.	27.0	335
5	Predictive factors of response and survival in myelodysplastic syndrome treated with erythropoietin and G-CSF: the GFM experience. <i>Blood</i> , 2008, 111, 574-582.	1.4	295
6	Antileukemic activity of rapamycin in acute myeloid leukemia. <i>Blood</i> , 2005, 105, 2527-2534.	1.4	280
7	TET2 mutation is an independent favorable prognostic factor in myelodysplastic syndromes (MDSs). <i>Blood</i> , 2009, 114, 3285-3291.	1.4	264
8	TET2 gene mutation is a frequent and adverse event in chronic myelomonocytic leukemia. <i>Haematologica</i> , 2009, 94, 1676-1681.	3.5	234
9	Mutations affecting mRNA splicing define distinct clinical phenotypes and correlate with patient outcome in myelodysplastic syndromes. <i>Blood</i> , 2012, 119, 3211-3218.	1.4	220
10	Does iron chelation therapy improve survival in regularly transfused lower risk MDS patients? A multicenter study by the GFM. <i>Leukemia Research</i> , 2010, 34, 864-870.	0.8	183
11	Efficacy and safety of lenalidomide in intermediate-2 or high-risk myelodysplastic syndromes with 5q deletion: results of a phase 2 study. <i>Blood</i> , 2009, 113, 3947-3952.	1.4	158
12	The human spleen is a major reservoir for long-lived vaccinia virus-specific memory B cells. <i>Blood</i> , 2008, 111, 4653-4659.	1.4	145
13	Expression of Focal Adhesion Kinase in Acute Myeloid Leukemia Is Associated with Enhanced Blast Migration, Increased Cellularity, and Poor Prognosis. <i>Cancer Research</i> , 2004, 64, 3191-3197.	0.9	140
14	Sotatercept with long-term extension for the treatment of anaemia in patients with lower-risk myelodysplastic syndromes: a phase 2, dose-ranging trial. <i>Lancet Haematology</i> , 2018, 5, e63-e72.	4.6	95
15	Outcome of Lower-Risk Patients With Myelodysplastic Syndromes Without 5q Deletion After Failure of Erythropoiesis-Stimulating Agents. <i>Journal of Clinical Oncology</i> , 2017, 35, 1591-1597.	1.6	79
16	Prognostic value of self-reported fatigue on overall survival in patients with myelodysplastic syndromes: a multicentre, prospective, observational, cohort study. <i>Lancet Oncology</i> , 2015, 16, 1506-1514.	10.7	76
17	Prolonged survival with improved tolerability in higher-risk myelodysplastic syndromes: azacitidine compared with low dose ara-C. <i>British Journal of Haematology</i> , 2010, 149, 244-249.	2.5	75
18	Validation of the revised international prognostic scoring system (IPSS) in patients with lower-risk myelodysplastic syndromes: a report from the prospective European LeukaemiaNet (EUMDS) registry. <i>British Journal of Haematology</i> , 2015, 170, 372-383.	2.5	72

#	ARTICLE	IF	CITATIONS
19	Can the revised IPSS predict response to erythropoietic-stimulating agents in patients with classical IPSS low or intermediate-1 MDS?. <i>Blood</i> , 2013, 122, 2286-2288.	1.4	67
20	Newly diagnosed immune thrombocytopenia adults: Clinical epidemiology, exposure to treatments, and evolution. Results of the CARMEN multicenter prospective cohort. <i>American Journal of Hematology</i> , 2017, 92, 493-500.	4.1	67
21	Tumor necrosis factor alpha induces senescence and chromosomal instability in human leukemic cells. <i>Oncogene</i> , 2004, 23, 7507-7516.	5.9	63
22	APR-246 Combined with Azacitidine (AZA) in TP53 Mutated Myelodysplastic Syndrome (MDS) and Acute Myeloid Leukemia (AML). a Phase 2 Study By the Groupe Francophone Des Myélodysplasies (GFM). <i>Blood</i> , 2019, 134, 677-677.	1.4	62
23	Early introduction of ESA in low risk MDS patients may delay the need for RBC transfusion: A retrospective analysis on 112 patients. <i>Leukemia Research</i> , 2010, 34, 1430-1436.	0.8	60
24	Intensive chemotherapy, azacitidine, or supportive care in older acute myeloid leukemia patients: An analysis from a regional healthcare network. <i>American Journal of Hematology</i> , 2014, 89, E244-52.	4.1	59
25	Prevalence, severity and correlates of fatigue in newly diagnosed patients with myelodysplastic syndromes. <i>British Journal of Haematology</i> , 2015, 168, 361-370.	2.5	59
26	The Medalist Trial: Results of a Phase 3, Randomized, Double-Blind, Placebo-Controlled Study of Luspatercept to Treat Anemia in Patients with Very Low-, Low-, or Intermediate-Risk Myelodysplastic Syndromes (MDS) with Ring Sideroblasts (RS) Who Require Red Blood Cell (RBC) Transfusions. <i>Blood</i> , 2018, 132, 1-1.	1.4	57
27	A randomized phase II trial of azacitidine +/- epoetin- α in lower-risk myelodysplastic syndromes resistant to erythropoietic stimulating agents. <i>Haematologica</i> , 2016, 101, 918-925.	3.5	55
28	A non-randomised dose-escalating phase II study of thalidomide for the treatment of patients with low-risk myelodysplastic syndromes: the Thal-SMD-2000 trial of the Groupe Francais des Myelodysplasies. <i>British Journal of Haematology</i> , 2005, 131, 609-618.	2.5	44
29	Characteristics and outcome of myelodysplastic syndromes (MDS) with isolated 20q deletion: A report on 62 cases. <i>Leukemia Research</i> , 2011, 35, 863-867.	0.8	44
30	Tumor necrosis factor- β inhibits hTERT gene expression in human myeloid normal and leukemic cells. <i>Blood</i> , 2005, 106, 3200-3205.	1.4	41
31	Ribavirin for Chronic Hepatitis Prevention among Patients with Hematologic Malignancies. <i>Emerging Infectious Diseases</i> , 2015, 21, 1466-1469.	4.3	41
32	Are somatic mutations predictive of response to erythropoiesis stimulating agents in lower risk myelodysplastic syndromes?. <i>Haematologica</i> , 2016, 101, e280-e283.	3.5	41
33	A phase II study of guadecitabine in higher-risk myelodysplastic syndrome and low blast count acute myeloid leukemia after azacitidine failure. <i>Haematologica</i> , 2019, 104, 1565-1571.	3.5	39
34	Treatment by Lenalidomide in lower risk myelodysplastic syndrome with 5q deletion- The GFM experience. <i>Leukemia Research</i> , 2011, 35, 1444-1448.	0.8	36
35	Effect of lenalidomide treatment on clonal architecture of myelodysplastic syndromes without 5q deletion. <i>Blood</i> , 2016, 127, 749-760.	1.4	36
36	Impact of red blood cell transfusion dose density on progression-free survival in patients with lower-risk myelodysplastic syndromes. <i>Haematologica</i> , 2020, 105, 632-639.	3.5	35

#	ARTICLE	IF	CITATIONS
37	Outcomes in <sc>RBC</sc> transfusionâ€dependent patients with <sc>L</sc>owâ€<sc>I</sc>ntermediateâ€1â€risk myelodysplastic syndromes with isolated deletion 5q treated with lenalidomide: a subset analysis from the <sc>MDS</sc>â€004 study. European Journal of Haematology, 2014, 93, 429-438.	2.2	32
38	Immune checkpoint inhibitor-related acral vasculitis. , 2018, 6, 120.		32
39	Cardiac iron overload assessed by <sc>T</sc>2* magnetic resonance imaging and cardiac function in regularly transfused myelodysplastic syndrome patients. British Journal of Haematology, 2013, 162, 413-415.	2.5	29
40	An Open-Label, Phase 2, Dose-Finding Study of Sotatercept (ACE-011) in Patients with Low or Intermediate-1 (Int-1)-Risk Myelodysplastic Syndromes (MDS) or Non-Proliferative Chronic Myelomonocytic Leukemia (CMML) and Anemia Requiring Transfusion. Blood, 2014, 124, 3251-3251.	1.4	23
41	Transfusion-Dependency Is the Most Important Prognostic Factor for Survival in 1000 Newly Diagnosed MDS Patients with Low- and Intermediate-1 Risk MDS in the European LeukemiaNet MDS Registry. Blood, 2011, 118, 2775-2775.	1.4	20
42	Treatment of Lower Risk MDS with Del 5q with Lenalidomide (LEN): Results of the French ATU Program.. Blood, 2009, 114, 2764-2764.	1.4	20
43	Anti-PCNA antibodies: prevalence and predictive value. Joint Bone Spine, 2005, 72, 432-435.	1.6	19
44	Daily practice management of myelodysplastic syndromes in France: data from 907 patients in a one-week cross-sectional study by the Groupe Francophone des Myelodysplasies. Haematologica, 2010, 95, 892-899.	3.5	18
45	Combination of vorinostat and low dose cytarabine for patients with azacitidine-refractory/relapsed high risk myelodysplastic syndromes. Leukemia Research, 2014, 38, 29-33.	0.8	16
46	A phase I/II trial of Erlotinib in higher risk myelodysplastic syndromes and acute myeloid leukemia after azacitidine failure. Leukemia Research, 2014, 38, 1430-1434.	0.8	16
47	Myelodysplastic syndromes with single neutropenia or thrombocytopenia are rarely refractory cytopenias with unilineage dysplasia by World Health Organization 2008 criteria and have favourable prognosis. British Journal of Haematology, 2016, 175, 975-979.	2.5	15
48	The Impact of a Small Private Online Course as a New Approach to Teaching Oncology: Development and Evaluation. JMIR Medical Education, 2018, 4, e6.	2.6	15
49	Impact of Treatment with Iron Chelators in Lower-Risk MDS Patients Participating in the European Leukemianet MDS (EUMDS) Registry. Blood, 2016, 128, 3186-3186.	1.4	14
50	Prolonged Survival without Complete Remission (CR) In AML Patients (Pts) Treated with Azacitidine (AZA). Blood, 2010, 116, 2183-2183.	1.4	13
51	Validation of immune thrombocytopenia diagnosis code in the French hospital electronic database. European Journal of Internal Medicine, 2016, 32, e21-e22.	2.2	11
52	Azacitidine improves outcome in higherâ€risk <sc>MDS</sc> patients with chromosome 7 abnormalities: a retrospective comparison of <sc>GESMD</sc> and <sc>GFM</sc> registries. British Journal of Haematology, 2018, 181, 350-359.	2.5	11
53	Results of a Phase II Study of Guadecitabine (SGI-110) in Higher Risk MDS, CMML or Low Blast Count AML Patients Refractory to or Relapsing after Azacitidine (AZA) Treatment. Blood, 2016, 128, 347-347.	1.4	10
54	Small Private Online Course in Teaching Oncologyâ€Feedback After 1â€Year: What Lessons?. Journal of Cancer Education, 2021, 36, 65-71.	1.3	9

#	ARTICLE	IF	CITATIONS
55	A Randomized Phase II Study of Azacitidine (AZA) Alone or with Lenalidomide (LEN), Valproic Acid (VPA) or Idarubicin (IDA) in Higher-Risk MDS: Gfm's 'pick a Winner' Trial. <i>Blood</i> , 2018, 132, 467-467.	1.4	9
56	Clinical characteristics and outcomes according to age in lenalidomide-treated patients with RBC transfusion-dependent lower-risk MDS and del(5q). <i>Journal of Hematology and Oncology</i> , 2017, 10, 131.	17.0	8
57	Prospective evaluation of the effect of deferasirox on hematologic response in transfusion-dependent patients with low-risk MDS and iron overload. <i>European Journal of Haematology</i> , 2018, 101, 165-173.	2.2	7
58	Eltrombopag for the Treatment of Thrombocytopenia of Low and Intermediate-1 IPSS Risk Myelodysplastic Syndromes: Interim Results on Efficacy, Safety and Quality of Life of an International, Multicenter Prospective, Randomized, Trial. <i>Blood</i> , 2015, 126, 91-91.	1.4	7
59	Interim Results of A Randomized Phase II Trial of Azacitidine (AZA) +/â~ Epo In Lower Risk Myelodysplastic Syndrome (MDS) Resistant to An Erythropoietic Stimulating Agent (ESA) Alone. <i>Blood</i> , 2010, 116, 1880-1880.	1.4	6
60	Disease-Management of Low- and Intermediate-1 Risk Myelodysplastic Syndromes: Report on 800 Newly Diagnosed MDS Patients From the European LeukemiaNet MDS Registry. <i>Blood</i> , 2010, 116, 2917-2917.	1.4	5
61	Prognostic impact of a suboptimal number of analyzed metaphases in normal karyotype lower-risk MDS. <i>Leukemia Research</i> , 2018, 67, 21-26.	0.8	4
62	Prospective Evaluation of the Effect of Deferasirox on Hematologic Response in Transfusion-Dependent Patients with Low-Risk MDS and Iron Overload: The Rythmex Study. <i>Blood</i> , 2016, 128, 2008-2008.	1.4	4
63	Is Azacitidine (AZA) Really Effective in High Risk MDS Patients with Chromosome 7 Abnormalities (Abn) Tj ETQq1 1_0_784314_4rgBT/O	1.4	4
64	Re: Severe Primary Autoimmune Thrombocytopenia (<sc>ITP</sc>) in Pregnancy: a national cohort study Primary immune thrombocytopenia management during pregnancy. A French study. <i>BJOG: an International Journal of Obstetrics and Gynaecology</i> , 2018, 125, 629-630.	2.3	3
65	FAS Gene Expression Is Epigenetically Regulated and Predicts the Responsiveness to Azacitidine In High-Risk Myelodysplastic Syndromes. <i>Blood</i> , 2010, 116, 232-232.	1.4	3
66	Validation Of The Revised International Prognostic Scoring System (IPSS-R) In 1000 Newly Diagnosed MDS Patients With Low- and Intermediate-1 Risk MDS In The European Leukemianet MDS (EUMDS) Registry. <i>Blood</i> , 2013, 122, 2770-2770.	1.4	3
67	Treatment of Advanced Systemic Mastocytosis with PKC412: The French Compassionate Use Programme Experience and Historical Comparison. <i>Blood</i> , 2014, 124, 3193-3193.	1.4	3
68	Clinical Epidemiology and First-Line Treatment in Immune Thrombocytopenia Adults. Results of the Carmen Prospective Cohort. <i>Blood</i> , 2015, 126, 3473-3473.	1.4	3
69	Pretreatment with standard-dose intravenous methylprednisolone does not improve outcomes in newly diagnosed immune thrombocytopenia (<sc>ITP</sc>). <i>European Journal of Haematology</i> , 2018, 100, 412-418.	2.2	2
70	Myelodysplastic Syndrome (MDS) in France: Results of a One-Week Cross-Sectional Survey on Daily Practice Management in 919 Patients by the GFM. <i>Blood</i> , 2008, 112, 2672-2672.	1.4	2
71	Should Immunosuppressive Therapy (IST) Be Used More Often In Lower Risk MDS?. <i>Blood</i> , 2010, 116, 1868-1868.	1.4	1
72	Health-Related Quality of Life In Newly Diagnosed Low Risk and Intermediate-1 Risk MDS: Report on the First 683 Patients From the European LeukemiaNet Registry. <i>Blood</i> , 2010, 116, 3999-3999.	1.4	1

#	ARTICLE	IF	CITATIONS
73	Home Azacitidine Administration in High Risk Myelodysplastic Syndromes: Favorable Results of a Pilot Study in 48 Patients. <i>Blood</i> , 2011, 118, 1719-1719.	1.4	1
74	Prognostic Factors of Response to Erythropoiesis Stimulating Agents (ESA) Treatment in Non RBC Transfusion Dependent Lower Risk MDS. Preliminary Results of a French and Italian Study (on behalf of the European Myelodysplastic Syndromes Study Group). <i>Blood</i> , 2010, 116, 1719-1719.	1.4	0
75	Comprehensive Genetic Screening of Chronic Myelomonocytic Leukemias (CMML). <i>Blood</i> , 2012, 120, 3811-3811.	1.4	1
76	NPM1 Expression Level and a CRBN Polymorphism Are Able to Predict the Rate of Response to Lenalidomide in Non Del(5q) Lower Risk MDS Patients Resistant to Erythropoiesis-Stimulating Agents: The GFM Experience. <i>Blood</i> , 2014, 124, 533-533.	1.4	1
77	Long-Term Outcome of Anemic Non Del 5q Lower-Risk MDS Refractory to or Relapsing After Erythropoiesis Stimulating Agents (ESAs). <i>Blood</i> , 2010, 116, 442-442.	1.4	1
78	The Revised IPSS (IPSS-R) Predicts Response To Erythropoietic Stimulating agents (ESA) In Pts With Classical IPSS Low Or Intermediate-1 (int 1)- MDS: A Joint Retrospective Study Of The GFM, Düsseldorf and Fism. <i>Blood</i> , 2013, 122, 2761-2761.	1.4	1
79	Outcome of Lower Risk Non Del 5q MDS after Failure of Erythropoiesis Stimulating Agents (ESA), and Impact of Post-ESA Treatment on Survival: A Retrospective European Study. <i>Blood</i> , 2015, 126, 1665-1665.	1.4	1
80	Activity of Rapamycin in Patients with Relapsed, Refractory or Poor-Risk Acute Myeloid Leukemia.. <i>Blood</i> , 2004, 104, 1791-1791.	1.4	0
81	Both the Endoplasmic Reticulum and the Mitochondria Are Involved in Apoptosis of Erythroid Precursors in Low Grade Myelodysplastic Syndromes.. <i>Blood</i> , 2006, 108, 2638-2638.	1.4	0
82	Fas-Dependent Apoptosis in Early MDS Erythroid Precursors Involves Endoplasmic Reticulum.. <i>Blood</i> , 2007, 110, 3346-3346.	1.4	0
83	Prognostic Impact of JAK2V617F Mutation In MDS: a Matched Case Control Study. <i>Blood</i> , 2010, 116, 440-440.	1.4	0
84	Prognostic Factors of Long-Term Outcomes In Low- or Int-1-Risk MDS with del5q Treated with Lenalidomide (LEN): Results From a Randomized Phase 3 Trial (MDS-004). <i>Blood</i> , 2010, 116, 4027-4027.	1.4	0
85	Correlation Between serum ferritin Level at diagnosis and Survival In Lower Risk, Non-Transfusion Dependent, MDS Patients.A Report by the Groupe Francophone Des Myelodysplasies (GFM). <i>Blood</i> , 2010, 116, 2916-2916.	1.4	0
86	A Prognostic Score for Overall Survival (OS) with Azacitidine (AZA) In Higher Risk MDS Based on 282 Patients (pts), and Validated In 175 Pts From the AZA 001 Trial. <i>Blood</i> , 2010, 116, 3996-3996.	1.4	0
87	BCOR Mutations Represent an Independent Factor of Poor Prognosis in Myelodysplastic Syndromes. <i>Blood</i> , 2012, 120, 1697-1697.	1.4	0
88	A phase I /II Trial of Erlotinib in Higher Risk MDS After Azacitidine (AZA) Failure. <i>Blood</i> , 2012, 120, 1719-1719.	1.4	0
89	Outcomes In RBC Transfusion-Dependent Patients (Pts) With Low-/Intermediate (Int)-1-Risk Myelodysplastic Syndromes (MDS) With Isolated Deletion 5q Treated With Lenalidomide (LEN): A Subset Analysis From The MDS-004 Study. <i>Blood</i> , 2013, 122, 2753-2753.	1.4	0
90	Markers of Oxidative Stress Do Not Correlate with Labile Plasma Iron Blood in Patients with Myelodysplastic Syndromes. <i>Blood</i> , 2015, 126, 2149-2149.	1.4	0

#	ARTICLE	IF	CITATIONS
91	Prognostic Impact of Transfusions Intensity on Survival and Development of Thrombocytopenia in Newly Diagnosed Lower-Risk MDS Patients Participating in the European Leukemianet EU-MDS Registry. Blood, 2015, 126, 1677-1677.	1.4	0
92	Incidence of Adverse Drug Reactions Related to Immune Thrombocytopenia Drugs. A Prospective Cohort Study. Blood, 2015, 126, 1056-1056.	1.4	0
93	Interest in Initiating Corticosteroids By Intravenous Methylprednisolone at Standard Dose in Newly Diagnosed Immune Thrombocytopenia Adults: Results of the Prospective Carmen Registry. Blood, 2016, 128, 3736-3736.	1.4	0
94	Positivity Rates of Tests Used at Immune Thrombocytopenia Diagnosis to Detect Associated Diseases. a Prospective Multicenter Cohort Study of 218 Patients. Blood, 2016, 128, 1367-1367.	1.4	0